Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present BrainStorm Cell Therapeutics Inc. (OTC: BCLI).

Full DD Report for BCLI

Recent News from (OTC: BCLI)

BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New York
NEW YORK and PETACH TIKVAH, Israel , April 11, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will present at ...
Source: PR Newswire
Date: April, 11 2018 01:00
Your Daily Pharma Scoop: Sorrento Sell-Off, Bluebird/Celgene Agreement, Edge Therapeutics' Setback
A nalysis focus: Sorrento Sorrento Therapeutics (SRNE) shares are down nearly 25%. Shares have been dragged lower by the convertible debt deal announced on Tuesday, as well as, a cautious article published on Seeking Alpha. The article published by J Capital raises sev...
Source: SeekingAlpha
Date: March, 29 2018 08:00
BrainStorm Cell Therapeutics' Phase 3 trial of NurOwn in ALS now open to Canadian patients
BrainStorm Cell Therapeutics (NASDAQ: BCLI ) amends the protocol of its Phase 3 clinical trial of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS) by opening the enrollment to Canada-based ALS patients. More news on: BrainStorm Cell Therapeutics Inc., Healthcare ...
Source: SeekingAlpha
Date: March, 28 2018 07:42
BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients
NEW YORK and PETACH TIKVAH, Israel , March 28, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announces that it has amended  the protocol of its Phase 3 clinical trial ...
Source: PR Newswire
Date: March, 28 2018 05:54
Brainstorm Cell Therapeutics (BCLI) Presents At The Wall Street Investor Forum 26th Annual Growth Conference - Slideshow
The following slide deck was published by BrainStorm Cell Therapeutics Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: March, 26 2018 14:47
BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board
HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 21, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced the appointments of Stanley H. Appel , M.D., and Amit Bar-...
Source: PR Newswire
Date: March, 21 2018 08:00
Key events next week - healthcare
Noteworthy events for the week of March 18 - 24 for healthcare investors: More news on: Spark Therapeutics, SELLAS Life Sciences Group, Inc., Atara Biotherapeutics, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 16 2018 10:25
BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum
HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 15, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President & Chi...
Source: PR Newswire
Date: March, 15 2018 12:27
Innovate Biopharmaceuticals appoints June Almenoff, M.D., Ph.D. as Chief Operating Officer and Chief Medical Officer
Dr. Almenoff brings more than 20 years of pharmaceutical executive experience from GlaxoSmithKline and from Furiex Pharmaceuticals, where as President and Chief Medical Officer, she oversaw the development of Viberzi ® .  Almenoff will lead the development of Innovate...
Source: GlobeNewswire
Date: March, 13 2018 07:32
BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to Chair
HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 12, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today the formation of its Scientific Advisory Board (SAB) and...
Source: PR Newswire
Date: March, 12 2018 01:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-193.363.393.463.3619,394
2018-04-183.363.393.463.3619,394
2018-04-173.323.403.453.3246,428
2018-04-163.313.333.443.2921,466
2018-04-153.323.333.453.3063,465

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report.


About BrainStorm Cell Therapeutics Inc. (OTC: BCLI)

Logo for BrainStorm Cell Therapeutics Inc. (OTC: BCLI)

BrainStorm Cell Therapeutics Inc. is a clinical stage biotechnological company developing innovative, adult stem cell therapeutic products, derived from autologous bone marrow cells, for the treatment of highly debilitating neurodegenerative disorders. The company s current primary targets are Amyotrophic Lateral Sclerosis ALS, also known as Lou Gehrig s disease and Parkinson s disease PD . These devastating diseases have no treatment options and as such represent highly unmet medical needs. Upon completion of BrainStorm s clinical trials program and regulatory approvals, this novel therapy will provide compelling medical and economic benefits for patients, medical practitioners, and insurance/healthcare providers. By redirecting the inherent regenerative capacities of adult stem cells towards treating the basic disease pathologies, BrainStorm will enable healthcare institutions and society at large to realize massive savings in treatment and care costs. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of the Tel Aviv University.

 

 

 

Current Management

  • Anthony Fiorino / CEO
  • Chaim Lebovits / President
  • Liat Sossover / CFO
  • Adrian Harel / IR
  • Irit Arbel /
  • Mordechai Friedman /
  • Alon Pinkas /
  • Chen Schor /
  • Dr. Robert Shorr /
  • Malcolm Taub /

Current Share Structure

  • Market Cap: $61,977,630 - 03/20/2018
  • Issue and Outstanding: 19,070,040 - 03/06/2018

 


Recent Filings from (OTC: BCLI)

Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 20 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 20 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 13 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 03 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: October, 17 2017
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: September, 14 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 14 2017

 

 


Daily Technical Chart for (OTC: BCLI)

Daily Technical Chart for (OTC: BCLI)


Stay tuned for daily updates and more on (OTC: BCLI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BCLI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BCLI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BCLI and does not buy, sell, or trade any shares of BCLI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/

 

 

Release this Report to Investors

Via Email

Via Text

Important

If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us